Johnson & Johnson / Janssen pipeline at a glance (March 2026)
About the Johnson & Johnson / Janssen clinical program
Following the separation of the consumer business, Johnson & Johnson's pharmaceutical arm (Janssen) operates one of the strongest oncology and immunology pipelines in the industry. In hematology, Darzalex (daratumumab) for multiple myeloma continues expanding into earlier lines and new combinations, while Carvykti (ciltacabtagene autoleucel), the BCMA CAR-T therapy, advances into earlier myeloma settings. Rybrevant (amivantamab), the EGFR-MET bispecific antibody for NSCLC, is rapidly expanding with combination programs including lazertinib. In prostate cancer, Erleada (apalutamide) and Akeega (niraparib/abiraterone) address different molecular subgroups. Their immunology pipeline spans Stelara (ustekinumab), Tremfya (guselkumab), and a next-generation IL-23/IL-17 portfolio.
Key therapeutic areas
- Hematology (multiple myeloma, CAR-T)
- Thoracic oncology (EGFR-MET bispecific)
- Prostate cancer
- Immunology / dermatology (IL-23, IL-17)
- Solid tumor immuno-oncology
Key pipeline programs
- Darzalex (daratumumab) — CD38, multiple myeloma
- Carvykti (ciltacabtagene autoleucel) — BCMA CAR-T
- Rybrevant (amivantamab) — EGFR-MET bispecific, NSCLC
- Erleada (apalutamide) — non-metastatic/metastatic CRPC
- Akeega (niraparib + abiraterone) — HRR-mutated prostate
- Tremfya (guselkumab) — IL-23p19, psoriasis/IBD
Monitor the Johnson & Johnson / Janssen pipeline daily
Get alerts when Johnson & Johnson / Janssen registers new trials or updates existing protocols. Free 14-day trial — no credit card required.
Start Monitoring FreeTop Johnson & Johnson / Janssen trial indications
| Condition / Indication | Trials |
|---|---|
| ["Multiple Myeloma"] | 22 |
| ["Carcinoma, Non-Small-Cell Lung"] | 12 |
| ["Prostatic Neoplasms"] | 8 |
| ["Arthritis, Psoriatic"] | 8 |
| ["Non-Muscle Invasive Bladder Neoplasms"] | 6 |
| ["Colitis, Ulcerative"] | 6 |
| ["Plaque Psoriasis"] | 6 |
| ["Depressive Disorder, Major"] | 5 |
Why monitor Johnson & Johnson / Janssen's clinical trial activity
J&J's Rybrevant + lazertinib combination represents the most significant competitive threat to Tagrisso (osimertinib) in EGFR-mutant NSCLC. Any company active in lung cancer or multiple myeloma must monitor Janssen's Phase 3 pipeline in those indications.
DataLookout monitors ClinicalTrials.gov daily and surfaces changes to Johnson & Johnson / Janssen's registered studies — new trial registrations, status transitions (e.g., "Not yet recruiting" → "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and real-time pipeline developments.
How DataLookout tracks Johnson & Johnson / Janssen trials
- Sponsor normalization: Johnson & Johnson / Janssen may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
- Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
- Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced — not just new registrations.
- Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
- Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.
Automate your Johnson & Johnson / Janssen pipeline intelligence
Used by pharma BD, strategy, and competitive intelligence professionals. Setup takes under 5 minutes.
Start Free TrialFrequently asked questions
What is J&J/Janssen's focus in current clinical trials?
Janssen's most active trial areas are multiple myeloma (Darzalex combinations, Carvykti in earlier lines), NSCLC (Rybrevant amivantamab combinations), prostate cancer (Erleada, Akeega), and immunology (Tremfya, next-generation IL-23 inhibitors).
How many J&J/Janssen trials are currently recruiting?
Based on current ClinicalTrials.gov data, 70 Janssen/J&J-sponsored trials are actively recruiting patients globally.
Does DataLookout normalize 'Janssen' and 'Johnson & Johnson' as the same sponsor?
Yes. DataLookout's sponsor normalization maps Janssen Research & Development LLC, Janssen Biotech, Janssen Pharmaceutica, and related entities to a single canonical J&J/Janssen entry for complete pipeline visibility.